You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Sarepta expects DM1 and FSHD programs to enter registrational studies within 12 months, with potential for accelerated approval, while Huntington's proof of biologic activity is anticipated around the middle of next year.
Sarepta Therapeutics raised 2026 total net product revenue guidance to $1.25 to $1.3 billion, citing stabilized Elevitus demand and strong PMO performance. The company also plans to share multiple-dose data for its DM1 and FSHD programs and prepare registrational studies.
Sarepta Therapeutics reported net product revenues of approximately $323.8 million, raised full-year product-revenue guidance to $1.25 billion to $1.3 billion, and expects SRP-1003 and SRP-1001 multiple-ascending-dose data in the fourth quarter of 2026.
Sarepta Therapeutics reported nine-month net income of $297,608 thousand versus a $301,184 thousand loss, while collaboration and other revenue reached $530,438 thousand.
Sarepta Therapeutics, Inc. entered a settlement on September 23, 2026 with REGENXBIO, UPenn and Catalent resolving patent litigation, requiring Sarepta to pay REGENXBIO $39.0 million and securing patent non-suit commitments covering ELEVIDYS and AAVrh74-based gene therapy products.
Useful current figures from the complete screener profile.
TL;DR. Sarepta delivered Q2 GAAP and non-GAAP operating profitability on $328.7M in net product revenue, narrowed 2026 net product revenue guidance to $1.2–$1.3B (toward the low end) and tightened non-GAAP opex to $800–$850M, while raising collaboration/other revenue guidance by $75M at the midpoint; FDA accepted sNDAs for Elevidys/Amondys 45 and Vyondys 53 conversion to traditional approval, and DM1/FSHD MAD readouts remain on track for 2H 2026 with Elevidys Cohort 8 full enrollment by year-end and 12-week data in Q1 2027.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRPT
this stock
Sarepta Therapeutics, Inc.
|
$1.72B | -25.3% | +15.6% | — | 18.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Sarepta expects DM1 and FSHD programs to enter registrational studies within 12 months, with potential for accelerated approval, while Huntington's proof of biologic activity is anticipated around the middle of next year.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRPT | -9.8% | -6.0% | -3.6% | -13.7% | -25.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -12.4% | -4.9% | -4.1% | -13.5% | -36.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
